Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation At 2023 Metastatic Breast Cancer Research Conference
Portfolio Pulse from Benzinga Newsdesk
Sermonix Pharmaceuticals presented an update on their ELAINE-2 study at the 2023 Metastatic Breast Cancer Research Conference. The study focuses on the treatment of ER+/HER2-, ESR1-mutated, metastatic breast cancer with Lasofoxifene plus abemaciclib after progression on prior therapies.
September 05, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sermonix Pharmaceuticals, which may be related to LGND, presented an update on their ELAINE-2 study. The news could potentially impact LGND's stock price.
The news about Sermonix Pharmaceuticals' ELAINE-2 study update could potentially impact LGND's stock price. However, the article does not provide enough information to determine the exact nature of the relationship between Sermonix and LGND, or the potential impact on LGND's stock price.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50